TrialLeukemia2017

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

R Hehlmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.